At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of ...

Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

CVS is now covering long-acting injectable PrEP, representing a shift from last year when the pharmacy giant announced it was ...

Speaking at the J.P. Morgan Healthcare Conference 2026, CEO Daniel O’Day said that the company has seven pipeline drugs for ...

Pharmaceutical patent protection can be extended when drug companies bring newer products to market before their first patent ...

Seeking to prevent the spread of HIV, Unitaid is providing $31 million to South Africa and Zambia in hopes of widening access ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

Since my article from October, "What To Expect From Gilead in Q3 2025", Gilead Sciences' stock ( GILD) reached an all-time ...

Among treatment-naive adults with advanced HIV disease, integrase inhibitors are a preferred first-line therapy over protease inhibitors.

The CDC estimates 2.2 million Americans could benefit from HIV prevention drugs, but just over a quarter of that group have ...

Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO ...